• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Safety and efficacy of GABAA α5 antagonist S44819 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled trial
Publication date: March 2020Source: The Lancet Neurology, Volume 19, Issue 3Author(s): Hugues Chabriat, Claudio L Bassetti, Ute Marx, Marie-Laure Audoli-Inthavong, Aurore Sors, Estelle Lambert, Marine Wattez, Dirk M Hermann, Katharina ALTHAUS, Sergi AMARO, Hee-Joon BAE, Zbigniew BAK, Leonardo BARBARINI, Pietro BASSI, Rodrigo BAZAN, Daniel BERECZKI, Tomasz BERKOWICZ, Joerg BERROUSCHOT, Dylan BLACQUIERE, Waldemar BROLASummaryBackgroundS44819, a selective GABAA α5 receptor antagonist, reduces tonic post-ischaemic inhibition of the peri-infarct cortex. S44819 improved stroke recovery in rodents and increased cortical excitabi...
Source: The Lancet Neurology - February 19, 2020 Category: Neurology Source Type: research

Prediction of late seizures after ischaemic stroke with a novel prognostic model (the SeLECT score): a multivariable prediction model development and validation study
Publication date: February 2018 Source:The Lancet Neurology, Volume 17, Issue 2 Author(s): Marian Galovic, Nico Döhler, Barbara Erdélyi-Canavese, Ansgar Felbecker, Philip Siebel, Julian Conrad, Stefan Evers, Michael Winklehner, Tim J von Oertzen, Hans-Peter Haring, Anna Serafini, Giorgia Gregoraci, Mariarosaria Valente, Francesco Janes, Gian Luigi Gigli, Mark R Keezer, John S Duncan, Josemir W Sander, Matthias J Koepp, Barbara Tettenborn Background Stroke is one of the leading causes of acquired epilepsy in adults. An instrument to predict whether people are at high risk of developing post-stroke seizures is not availab...
Source: The Lancet Neurology - January 18, 2018 Category: Neurology Source Type: research